随机试验中维生素D补充与结直肠腺瘤或锯齿状息肉风险无关
VITAL试验预设辅助研究纳入25,871名无癌症和心血管病史的成人,随机接受每日2000 IU维生素D3加1 g海洋n-3脂肪酸或安慰剂。中位随访5.3年,维生素D组与传统腺瘤风险(OR 1.08;95%CI 0.92-1.27)及锯齿状息肉风险(OR 1.02;95%CI 0.82-1.26)均无显著关联。
要点
- 每日2000 IU维生素D3未降低平均风险成人结直肠腺瘤或锯齿状息肉风险。
- 补充与息肉大小、部位、数量或组织学特征无关。
- 基线25(OH)D低于30 ng/mL者补充与常规腺瘤OR 0.82(95%CI 0.60-1.13),需进一步研究。
核心结论
- 在未筛选维生素D缺乏的平均风险成人中,每日补充2000 IU维生素D3与结直肠癌前病变风险无关。
研究设计与样本
- VITAL试验预设辅助研究,25,871名无癌症和心血管病史成人(12,786名≥50岁男性,13,085名≥55岁女性)随机接受每日2000 IU维生素D3加1 g海洋n-3脂肪酸或安慰剂。
主要发现
- 中位随访5.3年,维生素D组12,927人中308例传统腺瘤,安慰剂组12,944人中287例,OR 1.08(95%CI 0.92-1.27)。
- 维生素D组172例锯齿状息肉,安慰剂组169例,OR 1.02(95%CI 0.82-1.26)。
- 补充与息肉大小、部位、数量或组织学特征无关。
临床怎么用
- 不应以预防结直肠腺瘤或锯齿状息肉为目的常规推荐平均风险成人补充维生素D。
- 基线维生素D水平低者补充的潜在获益需进一步研究,暂不据此改变临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The effects of vitamin D on risk of colorectal cancer precursors are not clear. We examined the influence of vitamin D supplementation on risk of colorectal adenomas and serrated polyps in a prespecified ancillary study of a large-scale prevention trial (the vitamin D and omegA-3 trial, VITAL) of individuals who were free of cancer and cardiovascular disease at enrollment. METHODS: In VITAL trial, 25,871 adults with no history of cancer or cardiovascular disease (12,786 men 50 years or older and 13,085 women 55 years or older) were randomly assigned to groups given daily dietary supplements (2000 IU vitamin D3 and 1 g marine n-3 fatty acid) or placebo. Patients were assigned to groups from November 2011 through March 2014 and the study ended on December 31, 2017. We confirmed conventional adenomas and serrated polyps by reviewing histopathology reports from participants who had reported a diagnosis of polyps and were asked by their doctors to return for a repeat colonoscopy or sigmoidoscopy in 5 years or less. We calculated the odds ratios (ORs) and 95% CIs by logistic regression, after adjusting for age, sex, n-3 treatment assignment, and history of endoscopy at time of randomization. RESULTS: During a median follow-up of 5.3 years, we documented 308 cases of conventional adenomas in 12,927 participants in the vitamin D group and 287 cases in 12,944 participants in the placebo group (OR for the association of vitamin D supplementation with adenoma, 1.08; 95% CI, 0.92-1.27). There were 172 cases of serrated polyps in the vitamin D group and 169 cases in the placebo group (OR for the association of vitamin D supplementation with serrated polyp, 1.02; 95% CI, 0.82-1.26). Supplementation was not associated with polyp size, location, multiplicity, or histologic features. We found evidence for an interaction between vitamin D supplementation and serum level of 25-hydroxyvitamin D, measured in 15,787 participants at randomization. Among individuals with serum levels of 25-hydroxyvitamin D below 30 ng/mL, the OR associated with supplementation for conventional adenoma was 0.82 (95% CI, 0.60-1.13), whereas among individuals with serum levels of 25-hydroxyvitamin D above 30 ng/mL, the OR for conventional adenoma was 1.20 (95% CI, 0.92-1.55) (P for interaction = .07). There was a significant interaction between vitamin D supplementation and serum level of 25-hydroxyvitamin D in their association with advanced adenoma (P for interaction = .04). CONCLUSIONS: Based on an ancillary study of data from the VITAL trial, daily vitamin D supplementation (2000 IU) was not associated with risk of colorectal cancer precursors in average-risk adults not selected for vitamin D insufficiency. A potential benefit for individuals with low baseline level of vitamin D requires further investigation. ClinicalTrials.gov number: NCT01169259.
引用
- Song M, Lee IM, Manson JE, et al. No Association Between Vitamin D Supplementation and Risk of Colorectal Adenomas or Serrated Polyps in a Randomized Trial. Clin Gastroenterol Hepatol. 2020. PMID: 32062040. doi:10.1016/j.cgh.2020.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。